| Useful Advices |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Sales Management > Increase Your Pipeline: Deploying the Cost Effective Sales Team |
|
Useful Advices - Increase Your Pipeline: Deploying the Cost Effective Sales Team
Based on my talks with local executives, indicators point toward our getting back to business. Many companie According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product s that were taking a wait and see stance on Sales are now beginning to once again invest in selling. As we ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ll know from the go-go days, deploying a new sales team takes significant investment, especially if the sale lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. cycle is lengthy. When venture investment was pouring in, I saw scores of companies spend months building a here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe d investing in a sales infrastructure before a single call was made! Their new sales VP would first start hi d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro s search for regional managers who would subsequently recruit field reps. And then, after the grand sales ki ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc k off, it was 6-9 months before the first sale! This just isn’t practical for most companies, regardless of easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi the economic environment. Over the years, however, I’ve seen an extremely cost effective model being implem nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically nted by guerilla companies not flush with cash. The concept leverages the best of both inside and outside sa and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ les departments. If you run the numbers, you will see that an inside team is a fraction of the cost of an ou ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi side team, especially when you factor in travel, entertainment and other field related expenses. Additionall ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a , an inside lead generator can double – even triple – the effectiveness of an outside representative. Consi dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod der this: If a rep needs to make 100 contacts to generate 5 appointments, then he is essentially wasting 95% cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin of his calls. Okay, it’s not really wasting time, but if the sales reps were in front of qualified prospects tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen instead of talking to unqualified suspects, then their productivity would be significantly increased. The m t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel st cost effective model I’ve seen has been to employ inside lead generation to support the outside sales eff ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust orts. Rather than hire 3 outside reps, consider hiring 2 outside reps and 1 inside lead development or insid y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products sales rep to support them. The immediate benefits you will see include: Reduced payroll Reduced field . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de costs Centrally managed lead development process Increased productivity of outside reps M elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip re appointments into target accounts Better coverage of marginal accounts in dispersed geographic area tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Border Check: Recording Your Intellectual Property With U.S. Customs & Border Protection Magnificent Force of a Smile in Business Direct Mail Marketing and Customer Coupon Addictions
|